Dante Laboratories lands in Dubai, a state-of-the-art genome laboratory – Science and Technology – The New Europe

(ANSA) – L’Aquila, March 26 – Dante Laboratories, one of the world’s leading companies in genomics and precision medicine, lands in Dubai: The multinational has received the green light from the authorities of the United Arab Emirates. Dante Labs’ innovative and state-of-the-art sequencing center in Dubai, located on a prestigious site of more than 1,200 square metres, is licensed as a licensed medical genomics laboratory. This new license allows you to work in the following areas: clinical cytogenetics, clinical pathology, clinical genetics, cytogenetics, and medical genetics.

“We are very satisfied with this additional achievement in a very selective region of the world – explained Dante Labs CEO Andrea Riposati – and this new medical mandate constitutes an important step forward for the identification of advanced genetic solutions in the United Arab Emirates (UAE), for the benefit of 400 million Residing in the Middle East and beyond. The UAE has become one of the world leaders in genomics, and we are pleased to have invested in this beautiful region of the world.”

Dante Labs has built a state-of-the-art laboratory in Dubai Silicon Oasis. “This is an appreciation for the hard work of the local Dante Labs team – added Professor Capule, co-founder of the company – and we look forward to developing clinical solutions for the entire region and the rest of the world.” The multinational company has its nerve center in L’Aquila: it is present in 90 countries around the world. In recent days he participated in the mission as part of the Expo Dubai 2020, which is being promoted by the Abruzzo region through the operational arm of the Regional Agency for Productive Activities (ARAB). It is a global genome data company that creates and markets a new class of transformative applications for health and longevity based on whole genome sequencing and artificial intelligence. The multinational company’s assets include one of the research’s largest agreed-upon private genome databases, a proprietary software platform designed to harness the power of large-scale genetic data, and proprietary processes that enable an industrial approach to genetic sequencing. (handle).